A Pooled Analysis of 2618 Patients Treated with Trastuzumab Beyond Progression for Advanced Breast Cancer.

CONCLUSIONS: This pooled analysis confirms that continuing T beyond the first progression continues to be 1 of the effective and preferred choices in HER2+ MBC, failing a (T-based) first-line regimen. PMID: 23276465 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/PubMed/23276465?dopt=Abstract

Source: Clinical Breast Cancer - December 28, 2012 Category: Cancer & Oncology Authors: Petrelli F, Barni S Tags: Clin Breast Cancer Source Type: research